HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma

Conventional cytotoxic therapies for synovial sarcoma provide limited benefit, and no drugs specifically targeting its driving SS18-SSX fusion oncoprotein are currently available. Patients remain at high risk for early and late metastasis. A high-throughput drug screen consisting of over 900 tool co...

Descripción completa

Detalles Bibliográficos
Autores principales: Laporte, Aimée N., Barrott, Jared J., Yao, Ren Jie, Poulin, Neal M., Brodin, Bertha A., Jones, Kevin B., Underhill, T. Michael, Nielsen, Torsten O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215898/
https://www.ncbi.nlm.nih.gov/pubmed/28056055
http://dx.doi.org/10.1371/journal.pone.0169407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215898/
https://www.ncbi.nlm.nih.gov/pubmed/28056055
http://dx.doi.org/10.1371/journal.pone.0169407

Ejemplares similares